NORD Announces Research Grants Available for Study of Rare Diseases

By Jennifer Huron

The National Organization for Rare Disorders (NORD), the leading independent, nonprofit organization committed to the identification, treatment, and cures of rare diseases, has announced the availability of new research grants to study rare diseases. NORD’s 2016 research grant funding is available for the study of:

  • Appendix Cancer and Pseudomyxoma Peritonei – Two (2) grants of up to $50,000 for scientific and/or clinical research studies related to Appendix Cancer and/or Pseudomyxoma Peritonei (PMP). See full RFP and abstract template here.
  • Autoimmune Polyglandular Syndrome Type 1 – One (1) grant of up to $100,000 for scientific and/or clinical research studies related to Autoimmune Polyglandular Syndrome Type 1 (APS Type 1). See full RFP and abstract template here.
  • Homocystinuria – One (1) grant of up to $30,000 for scientific and/or clinical research studies related to Homocystinuria due to Cystathionine Beta-Synthase Deficiency. See full RFP and abstract template here.
  • Malonic Aciduria – One (1) grant of up to $30,000 for scientific and/or clinical research studies related to Malonic Aciduria. See full RFP and abstract template here.
  • Stiff Person Syndrome – One (1) grant of up to $30,000 for scientific and/or clinical research studies related to Stiff Person Syndrome. See full RFP and abstract templatehere.

These grants are made possible by donations to NORD. In some cases, the grants are co-sponsored by NORD and disease-specific patient organizations. NORD encourages all U.S. and international researchers interested in studying these diseases to consider applying.

The objective of the NORD Research Grant Program is to encourage meritorious scientific and clinical studies that will ultimately lead to new diagnostics, treatments, and/or cures for rare (also called “orphan”) diseases or disorders. The studies funded with NORD research grants provide preliminary data on drugs, devices or medical foods that researchers may then use to attract funding from government or industry sponsors to pursue further clinical studies. Two of NORD’s previous research grants have resulted in FDA-approved orphan products to treat rare diseases.

A rare disease is defined as one that affects fewer than 200,000 people in the U.S. There are 7,000 rare diseases that combined affect 30 million Americans, or 1 in every 10 people, more than half of whom are children. The majority of rare diseases have no treatment.